Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study

NCT01029652 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Gout

Interventions

DRUG: Canakinumab 150 mg
DRUG: Triamcinolone acetonide 40 mg
DRUG: Placebo to canakinumab
DRUG: Placebo to triamcinolone acetonide

Sponsor

Novartis Pharmaceuticals